Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03451383 · ClinicalTrials.gov registry record

Older Breast Cancer Patients: Risk for Cognitive Decline

A clinical trial of Cognitive Decline and Cancer, Breast, sponsored by Georgetown University.

Recruiting
Registry status
1,700
Enrollment target
1
Study location

NCT03451383 is a study of Cognitive Decline and Cancer, Breast that is actively recruiting participants, run by Georgetown University. The registered enrollment target is 1,700 participants, above the 1,122-participant average among 61 other Cognitive Decline trials with a reported enrollment target (52% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03451383, a study of Cognitive Decline and Cancer, Breast, is actively recruiting participants, sponsored by Georgetown University.

RECRUITING
Registry status
1,700 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition domains, measure associations between cognitive decline and QOL, and describe how genetic polymorphisms, inflammatory biomarkers, sleep and physical measures moderate cognitive outcomes. This study is being done nationally, with recruiting sites at Georgetown University, Montgomery General Hospital, Virginia Cancer Specialists, Washington Hospital Center, Reston Breast Care Specialists, Memorial Sloan-Kettering, Moffitt Cancer Center, City of Hope National Medical Center, Hackensack University Medical Center, Indiana University and University of California, Los Angeles.

Study Locations (1)

District of Columbia

  • Georgetown University - Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,700 participants
Start Date 2010-08-01
Est. Completion 2025-04-30

Sponsor

Georgetown University

227 total trials

What the Registry Record Tells You About NCT03451383

The ClinicalTrials.gov registry entry for NCT03451383 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,122-participant average among 61 other Cognitive Decline trials with a reported enrollment target (52% higher). The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cognitive Decline appearing as the primary indexed condition, and to 0 interventions.

NCT03451383 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT03451383 about?

NCT03451383 is a clinical study titled "Older Breast Cancer Patients: Risk for Cognitive Decline". The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition domains, measure associations between cognitive decline and QOL, and describe how genetic polymorphisms, inflammatory biomarkers, sleep and physi...

What is the current status of trial NCT03451383?

This trial is currently recruiting. The enrollment target is 1,700 participants. The study started on 2010-08-01. Estimated completion is 2025-04-30.

What conditions does trial NCT03451383 study?

This clinical trial studies the following conditions: Cognitive Decline, Cancer, Breast, Age-related Cognitive Decline.

Who is sponsoring clinical trial NCT03451383?

This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03451383 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cognitive Decline

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.